Array BioPharma Inc. announced the completion of both the binimetinib and encorafenib definitive agreements with Novartis.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
